MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer

作     者：Jian-Ping Cheng Ying Yan Xiang-Yi Wang Yuan-Li Lu Yan-Hua Yuan Jun Jia Jun Ren 

作者机构：Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Peking University School of Oncology Department of Medical Oncology Beijing Cancer Hospital & Institute Beijing 100142 P. R. China. 

出 版 物：《Chinese Journal of Cancer》 (CHINESE JOURNAL OF CANCER)

年 卷 期：2011年第30卷第1期

页      面：54-61页

核心收录：

学科分类：1002[医学-临床医学] 0905[农学-畜牧学] 09[农学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by Beijing Capital Development Foundation for Medical Sciences(No.2007-2053) 

主　　题：MUC1 治疗效果 肿瘤细胞 阳性率 乳腺癌 转移性 粘蛋白 化疗 

摘      要：Chemotherapy plays an important role in the treatment of metastatic breast cancer. It is important to monitor chemotherapeutic efficacy, to find a simple and efficient tool to guide treatment, and to predict the efficacy of treatment in a timely and accurate manner. This study aimed to detect mucin-1 (MUC1) - positive circulating tumor cells and MUC1 protein in the peripheral blood of patients with metastatic breast cancer and to investigate their relationship to chemotherapeutic efficacy. MUC1 mRNA was detected in the peripheral blood of 34 patients with newly diagnosed metastatic breast cancer by reverse transcription- polymerase chain reaction. The positive rates of MUC1 mRNA were 88.2% before chemotherapy and 70.6% after chemotherapy, without a significant difference (P = 0.564); MUC1 mRNA expression before chemotherapy had no correlation with treatment effectiveness (P = 0.281). The response rate of MUC1 mRNA -negative patients after first-cycle chemotherapy was significantly higher (P = 0.009) and the progression-free survival (PFS) was clearly longer than those of MUC1 mRNA-positive patients (P = 0.095). MUC1 protein in peripheral blood plasma was detected by an ELISA competitive inhibition assay. The patients with decreased MUC1 protein after chemotherapy had a significantly longer PFS than those with elevated MUC1 protein (P = 0.044). These results indicate that the outcomes of MUC1 mRNA - negative patients after chemotherapy are better than those of MUC1 mRNA-positive patients. In addition, patients with decreased expression of MUC1 protein have a better PFS.